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Background: Established on 1 June 2005, the University Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR) is the largest clinical trial registry in Japan, and joined the World Health Organization (WHO)
registry network in October 2008. Our aim was to understand the registration trend and overall characteristics of
Japan domestic, academic (non-industry-funded) clinical trials, which constitute the main body of registrations in
UMIN-CTR. In addition, we aimed to investigate the accessibility of clinical trials in UMIN-CTR to people worldwide,
as well as the accessibility of clinical trials conducted in Japan but registered abroad to Japanese people in the
Japanese language.
Methods: We obtained the data for registrations in UMIN-CTR from the UMIN Center, and extracted Japan
domestic, academic clinical trials to analyze their registration trend and overall characteristics. We also investigated
how many of the trials registered in UMIN-CTR could be accessed from the International Clinical Trials Registry
Platform (ICTRP). Finally, we searched ClinicalTrials.gov for all clinical trials conducted in Japan and investigated how
many of them were also registered in Japanese registries. All of the above analyses included clinical trials registered
from 2 June 2005 to 1 June 2010.
Results: During the period examined, the registration trend showed an obvious peak around September 2005 and
rapid growth from April 2009. Of the registered trials, 46.4% adopted a single-arm design, 34.5% used an active
control, only 10.9% were disclosed before trial commencement, and 90.0% did not publish any results. Overall,
3,063 of 3,064 clinical trials registered in UMIN-CTR could be accessed from ICTRP. Only 8.7% of all clinical trials
conducted in Japan and registered in ClinicalTrials.gov were also registered in Japanese registries.
Conclusions: The International Committee of Medical Journal Editors (ICMJE) announcements about clinical trial
registration and the Ethical Guidelines for Clinical Research published by the Japanese government are considered
to have promoted clinical trial registration in UMIN-CTR. However, problems associated with trial design,
retrospective registration, and publication of trial results need to be addressed in future. Almost all clinical trials
registered in UMIN-CTR are accessible to people worldwide through ICTRP. However, many trials conducted in
Japan but registered abroad cannot be accessed from Japanese registries in Japanese.
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Clinical trials are important for health professionals, re-
searchers, patients, and governments because they pro-
vide high quality evidence for clinical practice. However,
for various reasons, the actual situation of clinical trials
is less than satisfactory. Publication bias caused by se-
lective reporting of trials with positive results while
withholding trials with negative/neutral results has been
documented [1-3]. It is estimated that only half of all
controlled trials have been reported since the first ran-
domized controlled trial (RCT) in 1948 [4]. This will
lead to biased decision-making in clinical practice, devel-
opment of clinical practice guidelines, and resource allo-
cation. Furthermore, patients participate in clinical trials
as constituents of society, believing that they are con-
tributing to medical knowledge for patients in the future.
Hence, from an ethical perspective, trial results should
be considered to be an important part of social property
and given back to the public. Not reporting trial results
will damage the trust between patients and investigators,
as well as that between patients and research ethics re-
view boards [4]. Moreover, problems associated with
how to promote patient enrollment in clinical trials and
how to prevent possible intended modification of the
original protocol after the start of a trial remain to be
solved.
To address the problems stated above, registration of
clinical trials has been proposed as a possible solution
since the 1960s [5]. The value and importance of an inter-
national registry of all clinical trials were further empha-
sized by RJ Simes in 1986 [6]. The objective of clinical trial
registration is to make key information of all trials un-
dertaken accessible to the public, thereby increasing the
accountability and transparency of clinical trials, and redu-
cing the chance of publication bias. In 2004, the scandal of
concealment of safety problems in the clinical trial of par-
oxetine (Paxil; GlaxoSmithKline, Brentford, UK) aroused
international concern and prompted the development of
clinical trial registration [7,8]. In September 2004, the Inter-
national Committee of Medical Journal Editors (ICMJE)
announced their strategy to make the registration of clinical
trials a prerequisite for consideration of publication [9].
One month later, an open meeting to discuss the inter-
national principles for trial registration was held in Ottawa,
Canada. The resulting Ottawa statement detailed the re-
quirement for registration of the protocols and results of
all clinical trials [10].
In May 2005, the World Health Assembly endorsed a
resolution (WHA 58.34) to establish a voluntary platform
to link clinical trial registries to ensure a single point of ac-
cess, as well as the unambiguous identification of trials,
thereby enhancing access to information by patients, fam-
ilies, and patient groups [11]. This resolution led to the es-
tablishment of the International Clinical Trials RegistryPlatform (ICTRP) [12] by the World Health Organization
(WHO) in 2007. The WHO also published a 20-item Trial
Registration Data Set, which is considered to be the mini-
mum standard for full registration [13]. Moreover, since
its 2008 version, the Declaration of Helsinki by the World
Medical Association requires every clinical trial to be reg-
istered in a publicly accessible database before recruitment
of the first subject [14]. In addition, the Consolidated
Standards of Reporting Trials (CONSORT) Statement,
which has been adopted by most leading journals in the
field of clinical trials, requires reporting of the registration
number and name of the trial registry in item 23 [15].
In response to the global movement for clinical trial
registration, and also to help provide information on
clinical trials to Japanese nationals, the University Hos-
pital Medical Information Network (UMIN) commenced
the first Japanese clinical trials registry, UMIN-CTR
[16], on 1 June 2005. UMIN was established in 1989 as a
cooperative organization for national university hospitals
in Japan. It is sponsored by the Ministry of Education,
Culture, Sports, Science and Technology (MEXT) [17].
There are two other registries in Japan: the Japan
Pharmaceutical Information Center Clinical Trials Infor-
mation (Japic-CTI) [18] and the Japan Medical Associ-
ation Center for Clinical Trials (JMACCT) [19]. In
addition, an overall search portal for these three regis-
tries was established by the National Institute of Public
Health (NIPH) in October 2007. The three registries and
the search portal cooperate as a whole system and be-
came a WHO-ICTRP Primary Registry (Japan Primary
Registries Network, JPRN) in October 2008.
At present, the clinical trials conducted in Japan can be
divided into two categories: 1) clinical trials regulated
by Japanese Pharmaceutical Affairs Law (PAL) and Good
Clinical Practice (GCP), covering trials for new drug appli-
cation (called ‘Chiken’ in Japanese) and post-marketing
clinical trials sponsored by industry; and 2) other clinical
trials that are not regulated by Japanese PAL and GCP.
Most trials in this category are academic (non-industry-
funded) clinical trials.
For category 1, the notifications of protocols of clinical
trials for new drug application must be submitted to the
Ministry of Health and Welfare (MHW, reorganized to
be the Ministry of Health, Labour and Welfare (MHLW)
since 2001) for review before trial start since October
1979 [20]. On the other hand, the notifications of proto-
cols of post-marketing clinical trials sponsored by indus-
try have been required to be submitted to MHW for
review before trial start since December 1993 [21].
Although the annual number of notifications of clin-
ical trial protocols submitted for regulation review is
published on the Pharmaceuticals and Medical Devices
Agency (PMDA) website [22], their contents are not ac-
cessible to public. At present, there is no legal document
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egory 1 to be registered in a publicly accessible registry
in Japan.
However, to increase clinical trial transparency for the
benefit of patients and medical professionals, the Inter-
national Federation of Pharmaceutical Manufacturers &
Associations (IFPMA), the Japanese Pharmaceutical Man-
ufacturers Association (JPMA), the Pharmaceutical Re-
search and Manufacturers of America (PhRMA), and the
European Federation of Pharmaceutical Industries and As-
sociations (EFPIA) have approved the ‘Joint Position on
the Disclosure of Clinical Trial Information via Clinical
Trial Registries and Databases’ in January 2005 [23]. This
industrial joint position has been updated twice in
November 2008 and November 2009. According to the
latest version of this joint position (November 2009),
member companies are required to register all their clin-
ical trials in patients in a publicly accessible registry within
21 days of the start of patient enrollment [24].
Among more than 2,000 pharmaceutical companies in
Japan, 70 companies joined JPMA by July 2013. Al-
though the industrial joint position is neither a law nor a
governmental guideline, it is considered to have con-
straint force to some extent on member companies, to
promote the registration of clinical trials conducted by
them.
For clinical trials in category 2 (trials not regulated by
PAL or GCP), the Japanese government has taken the
following measures to improve their registration: 1)
since April 2007, MHLW has required registration in
Japanese registries for clinical trials as a pre-condition
for the application for Health and Labour Sciences Re-
search Grants [25]; and 2) since April 2009, the MHLW
has issued and applied the latest version of the Ethical
Guidelines for Clinical Research in Japan. It was this ver-
sion that first proposed the requirement for clinical trials
conducted in Japan to be registered in Japanese registries
[26]. Although the Ethical Guidelines for Clinical Re-
search are only administrative guidelines without legal
force, they are considered to be ‘soft’ law and perceived
as having effectiveness in regulating clinical research
conducted in Japan [27].
We summarized the regulations on clinical trial informa-
tion in Japan in Table 1, including the comparison with
relevant regulations in the USA. In the USA, the regis-
tration of all private and public clinical trials that test
effectiveness for ‘serious or life-threatening’ conditions sub-
mitted to the Food and Drug Administration (FDA) under
Investigational New Drug applications (INDs) was first
mandated by the FDA Modernization Act, section 113
(FDAMA 113) in 1997 [28]. ClinicalTrials.gov [29], one of
the most comprehensive registration platforms in the
world, was established in 2000 as the result of this law. It
accepts registrations of clinical trials all around the worldand operates as a service of the US National Institutes of
Health (NIH). Enacted since September 2007, Section 801
of the Food and Drug Administration Amendments Act
(FDAAA 801) has expanded the scope for registration to
be: interventional studies of drugs, biologics, and devices
(whether or not approved for marketing); phase 2 through
phase 4; at least one US site or IND or investigational de-
vice exemption (IDE) [30].
According to the results of our preliminary research, as
of 1 June 2010, the total number of registrations (clinical
trials and observational studies) in JPRN had reached
4,750 (UMIN-CTR: 3,595, 75.7%; Japic-CTI: 1,117, 23.5%;
JMACCT: 38, 0.8%). Overall, 92.5% (3,324/3,595) of regis-
trations in UMIN-CTR are academic (non-industry-
funded) clinical studies, while 98.2% (3,530/3,595) of
registrations in UMIN-CTR are domestic clinical studies
(conducted only in Japan). Industry-funded studies are
more likely to be registered in Japic-CTI, given that 94.0%
(1,050/1,117) of registered studies in Japic-CTI are funded
by industry. UMIN-CTR has been the main source of in-
formation for clinical studies registered in Japan, and the
major body of the registrations in UMIN-CTR is consti-
tuted by Japan domestic, academic clinical studies.
More than 2,000 new registrations were received in
UMIN-CTR in 2011, and the number of registrations is
likely to continue to increase in the future. However, no
systematic review of the registered clinical trials in
UMIN-CTR has been conducted. To understand the
registration trend and overall characteristics of the clin-
ical trials registered in UMIN-CTR, and to provide
insightful advice for the future improvement of Japanese
clinical trials, we conducted a retrospective analysis of
the clinical trials registered in UMIN-CTR in the first 5
years since its establishment (from 2 June 2005 to 1 June
2010). The focus of our analyses was on Japan domestic,
academic clinical trials because these studies constitute
the major body of all the registrations in UMIN-CTR,
and may have considerably different trial characteristics
from industry-funded or global studies. To reflect the
main characteristics of the clinical trials registered in
UMIN-CTR more precisely, we finally defined the object
of our analyses as Japan domestic, academic clinical tri-
als registered in UMIN-CTR in the first 5 years since its
inception.
Moreover, since UMIN-CTR was incorporated into
JPRN as a part of the primary registry of ICTRP at 3
years after its establishment, the aspect of whether the
clinical trials in UMIN-CTR, especially those trials regis-
tered before its incorporation into ICTRP, can be
accessed successfully through ICTRP became our con-
cern. Since this issue has not previously been investi-
gated, we analyzed the accessibility of the clinical trials
in UMIN-CTR to people around the world through
ICTRP. In addition, some clinical trials conducted in
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of whether such trials are also registered in Japanese
registries in the Japanese language remains unclear.
Therefore, we analyzed the accessibility of clinical trials
conducted in Japan but registered abroad to Japanese
people in the Japanese language.
Overall, our research involved four research questions.
First, how many Japan domestic, academic clinical trials
were registered each month in the first 5 years since the
establishment of UMIN-CTR? Second, what are the over-
all characteristics of the registered clinical trials? Third,
what is the accessibility of trials registered in UMIN-CTR
to people around the world through ICTRP? Fourth, what
is the accessibility of trials conducted in Japan (with atTable 1 Regulations on clinical trial information in Japan and
Date Japan
Clinical trials regulated by
PAL and GCP
Other clinical trials
October
1979
Notification of protocols of
clinical trials for new drug
application submitted to MHW
(required by PAL)
December
1993
Notification of protocols of
post-marketing clinical trials
submitted to MHWa
November
1997
January
2005
April 2007 Registration of clinical trials
with application for Health
and Labour Sciences
Research Grantsb
September
2007
November
2008
April 2009 Registration of all trials
conducted in Japan (required
by Ethical Guidelines for
Clinical Research)
November
2009
aRequired by Shin Iyakuhin Nado no Shiyo no Seiseki Nado ni Kansuru Cyosa Jisshi
new drugs) [21]; brequired by Heisei 19 Nendo Koseirodo Kagaku Kenkyuhi Hojyoki
Research Grants) [25]; cJoint Position on the Disclosure of Clinical Trial Information v
updated November 2008 and November 2009, by IFPMA, JPMA, PhRMA, and EFPIA
Associations; FDA, Food and Drug Administration; FDAAA, Food and Drug Administ
Act; GCP, Good Clinical Practice; IDE, investigational device exemption; IFPMA, Inter
Investigational New Drug application; JPMA, Japanese Pharmaceutical Manufacturer
Affairs Law; PhRMA, Pharmaceutical Research and Manufacturers of America.least one listed site in Japan) but registered abroad to
Japanese people in the Japanese language?
Methods
Registry
UMIN-CTR is a web-based registration platform that
accepts the registration of all types of clinical trials
and observational studies. According to the UMIN-CTR’s
principle, if Japan is included in the countries of recruit-
ment for a study, registration in both English and Japanese
is required. Otherwise, registration in English only is
acceptable. One UMIN unique trial number (study ID) is
generated automatically for the identification of each
registered trial [31].USA
USA Industrial positionc
Registration of all trials that test effectiveness
for ‘serious or life-threatening’ conditions
submitted to the FDA under INDs (required
by FDAMA 113)
Registration of all trials
except exploratory
trials
Registration of interventional studies of
drugs, biologics, and devices (whether or not
approved for marketing); phase 2 through 4;
at least one US site or IND or IDE (required
by FDAAA 801)
Registration of all
confirmatory clinical
trials and all
exploratory efficacy
trials
Registration of all
clinical trials in patients
Keikakusyo ni tsu i te (the notification of protocol of use results surveys on
n Kobo Yoko (requirement for the application of Health and Labour Sciences
ia Clinical Trial Registries and Databases (first version issued January 2005,
) [24]. EFPIA, European Federation of Pharmaceutical Industries and
ration Amendments Act; FDAMA, Food and Drug Administration Modernization
national Federation of Pharmaceutical Manufacturers & Associations; IND,
s Association; MHW, Ministry of Health and Welfare; PAL, Pharmaceutical
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Set and the requirement for registration information
proposed by the ICMJE, UMIN-CTR has added some
items according to local needs to form a set of 85 regis-
tration items [31]. These 85 items reflect the information
for a clinical trial on five domains [32]: basic informa-
tion; objective; design; administration information; and
progress. Approximately 53 of these items must be re-
gistered (this number may vary according to individual
trials). Most of the registered information will be access-
ible to the public from the date of disclosure, which can
be specified by the registrant. The registration and
search for clinical trial information are free.
With respect to the reporting of trial results in a clin-
ical trials registry, FDAAA 801 has mandated the sub-
mission of summary result data for certain trials of
drugs, biologics, and devices to ClinicalTrials.gov (gener-
ally not later than 1 year after the completion date) since
September 2008 [30]. ClinicalTrials.gov was expanded in
2008 to establish a results database for reporting trial re-
sults. On the other hand, reporting of trial results in
UMIN-CTR is optional, and no results database has yet
been established. Although the aspect of whether or not
the trial results have been published must be chosen
when registering a trial, the URL for published results
and detailed trial results in text form are only optional
items and are not mandated to be registered [31].
Data and screening
We obtained the full data containing all the registered
information of the registrations in UMIN-CTR from 2
June 2005 to 1 June 2010. We obtained these data from
the UMIN Center (downloaded on 18 January 2011),
and imported them into an Excel file for screening.
For research questions 1 and 2, we conducted three-
step screening to extract trials that were eligible for ana-
lyses. First, we analyzed the region/country of the registered
studies and extracted the Japan domestic studies. Next, we
analyzed the funding sources of the extracted studies and
excluded industry-funded studies. Finally, observational
studies were excluded and clinical trials were obtained for
further analyses.
For research question 3, we used the full data for the
registrations in UMIN-CTR from 2 June 2005 to 1 June
2010 for analyses. For research question 4, we chose
ClinicalTrials.gov as the object for analysis. We searched
ClinicalTrials.gov by specifying ‘Japan’ in the ‘country’
field, and ‘06/02/2005 to 06/01/2010’ in the ‘first re-
ceived’ field in the advanced search, to identify studies
conducted in Japan and registered during the analysis
period. We downloaded the information (20 items) for
the identified registrations into an Excel file and then ex-
cluded observational studies to obtain clinical trials for
analyses.Analysis methods
Research question 1: Monthly registration numbers of
clinical trials
The monthly numbers of registrations from 2 June 2005
to 1 June 2010 were plotted along a time axis to observe
the registration trend. The date of disclosure of trial in-
formation was taken as the registration date. This ana-
lysis was conducted from 11 April 2011 to 25 July 2011.
Research question 2: Overall characteristics of registered
trials
The information for registered items was examined by cat-
egorized analyses to understand the overall characteristics
of the registered clinical trials. The methods for cate-
gorization were based on the registration form of UMIN-
CTR. According to the local needs for information by
Japanese clinicians and researchers, 15 items were ana-
lyzed with primary concern and are discussed in this
article. Another 13 items were analyzed with secondary
concern and the results of these items will not be
discussed in this article (only presented in an additional
file for reference). The items of primary concern and sec-
ondary concern are listed in Table 2. This analysis was
conducted from 11 April 2011 to 25 July 2011.
Research question 3: Accessibility of trials registered in
UMIN-CTR through ICTRP
To study the accessibility of clinical trials registered in
UMIN-CTR to people around the world using ICTRP, we
estimated how many clinical trials registered in UMIN-
CTR from 2 June 2005 to 1 June 2010 could be accessed
from ICTRP. ICTRP is not a clinical trials registry. It pro-
vides a searchable database containing trial registration
datasets that are made available by data providers and pri-
mary registries around the world, including JPRN.
We first investigated the number of clinical trials and ob-
servational studies among all the registrations in UMIN-
CTR over 5 years (from 2 June 2005 to 1 June 2010). Two
types of study IDs (one beginning with ‘C00000’, which was
used in the early stage, and the other one beginning with
‘UMIN’, which is currently used) were assigned for these
studies and the following search of ICTRP was based on
these study IDs. Hence, we first divided all the studies into
two categories according to their ID type, and then investi-
gated the number of clinical trials and observational stud-
ies in each category.
Subsequently, we investigated how many of these stud-
ies could be accessed from ICTRP using three steps.
First, we searched ICTRP using ‘JPRN-UMIN*’ and
‘JPRN-C00000*’ in the basic search. ‘JPRN’ is used in
ICTRP to denote study records imported from Japanese
registries. The two identifiable strings in the study IDs
(‘C00000’ and ‘UMIN’) denote that a study is registered
in UMIN-CTR. Therefore, study records imported from
Table 2 Items of primary concern and secondary concern
for analyses
Primary concern Secondary concern
1. Malignancy/other 1. Objective
2. Genomic information 2. Developmental phase
3. Confirmatory/exploratory 3. Randomization unit
4. Explanatory/pragmatic 4. Stratification
5. Basic design 5. Dynamic allocation
6. Randomization 6. Institution consideration in
allocation
7. Blinding 7. Concealment
8. Control 8. Blocking in allocation
9. Number of arms 9. Purpose of intervention
10. Type of intervention 10. Lower age limit
11. Target sample size 11. Sex
12. Trial period 12. Primary sponsor
13. Publication of results 13. Funding source
14. Disclosure of trial before/after
trial start
15. Disease classification by specialty
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‘JPRN-UMIN’ or ‘JPRN-C00000’. All studies registered
should be assigned a study ID containing an identifiable
string representing the registry, meaning that we could
use the identifiable strings in IDs to search for studies
registered in specific registries. The identifiable strings
for several registries used in our research are shown in
Table 3.
Second, we noticed that some studies had multiple re-
cords in ICTRP, which were imported from different
registries because they were registered not only in
UMIN-CTR, but also in other registries. For some of
these studies, the records imported from other registries
were taken as the main records, while the records from
UMIN-CTR were the secondary records. Since second-
ary records cannot be searched on ICTRP, some studies
registered not only in UMIN-CTR, but also in other
registries may not be found in step 1. However, the main
records for such studies may contain the secondary IDs
assigned by UMIN-CTR. Hence, for the studies thatTable 3 Clinical trial registries and identifiable strings in
study IDs
Clinical trial registry Identifiable string in study ID
UMIN-CTR ‘UMIN’, ‘C00000’
Japic-CTI ‘Japic’
JMACCT ‘JMA’
ClinicalTrials.gov ‘NCT0’
Japic-CTI, Japan Pharmaceutical Information Center Clinical Trials Information;
JMACCT, Japan Medical Association Center for Clinical Trials; UMIN-CTR,
University Hospital Medical Information Network Clinical Trials Registry.were registered in UMIN-CTR during the 5-year period
but not found in step 1, we searched for their study IDs
assigned by UMIN-CTR in the ‘secondary ID’ field in
the advanced search on ICTRP to examine whether or
not they could be accessed.
Third, it was found that the records of some studies
imported from UMIN-CTR were not taken as the main
records, and that their study IDs assigned by UMIN-
CTR were also not contained in the corresponding main
records. Such studies cannot be found in either step 1 or
step 2. Hence, for the studies that were registered in
UMIN-CTR during the 5-year period but not found in
step 1 or step 2, we searched for them in a basic search
of ICTRP using their secondary IDs or titles registered
in UMIN-CTR as the search terms. For example, if study
‘C000000063’ was not found in step 1 or step 2, its sec-
ondary ID registered in UMIN-CTR, ‘NCT00131027’,
was searched for in ICTRP to see whether or not it
could be accessed.
Since this analysis was only focused on clinical trials
without observational studies, the studies that were reg-
istered in UMIN-CTR, but not found on ICTRP, by the
three-step search described above were checked to
examine whether or not they were clinical trials. Subse-
quently, the number of clinical trials that were registered
in UMIN-CTR in the 5-year period and accessible from
ICTRP was calculated.
Research question 4: Accessibility of trials conducted in
Japan (with at least one listed site in Japan) but registered
abroad to Japanese people in the Japanese language
We searched for clinical studies conducted in Japan
(with at least one listed site in Japan) and registered
from 2 June 2005 to 1 June 2010 (first received date) in
ClinicalTrials.gov. We then downloaded the relevant in-
formation (20 items) for the identified registrations into
an Excel file on 29 November 2012. We extracted the
clinical trials from these registrations and tried to assess
how many of them were also registered in Japanese
registries and accessible in the Japanese language.
If a trial was also registered in Japanese registries, an
identifiable string (‘C00000’, ‘UMIN’, ‘Japic’, or ‘JMA’)
should be found in the ‘other IDs’ item of that trial in
the downloaded data. Hence, we used the four identifi-
able strings to detect trials that were also registered in
Japanese registries.
We also noticed some trials that were first registered
in ClinicalTrials.gov and then registered in Japanese
registries. Such registrations in Japanese registries may
not be reported to ClinicalTrials.gov, and thus the IDs of
these trials issued by Japanese registries may be missing
in the data downloaded from ClinicalTrials.gov. How-
ever, the records of such trials in Japanese registries
should contain the IDs issued by ClinicalTrials.gov
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must be registered in Japanese registries. Therefore, we
also searched UMIN-CTR, Japic-CTI, and JMACCT for
complementation. We used the term ‘NCT0’ (an identi-
fiable string in the study IDs of ClinicalTrials.gov) to
search for UMIN-CTR in the ‘UMIN’s unique trial num-
ber or other study IDs’ field, Japic-CTI in the ‘full text
search’ field, and JMACCT in the ‘free word’ field. We
identified trials that were registered in Japanese registries
and ClinicalTrials.gov during the period of the analysis.
By summing up the results of such a double-sided
search and excluding duplicate records of the same trial,
we identified trials that were registered in Japanese re-
gistries and ClinicalTrials.gov among all the trials con-
ducted in Japan and registered in ClinicalTrials.gov from
2 June 2005 to 1 June 2010. We also analyzed the type
of funding source of these trials by categorizing them as
‘industry-funded’, ‘others-funded’ and ‘industry + others-
funded’. The rates of registration in Japanese registries
among clinical trials conducted in Japan and registered
in ClinicalTrials.gov were calculated in each category
and compared by a two-sided Fisher’s exact test (α =
0.05). All the analyses were conducted using Microsoft
Excel 2007 (Microsoft, Seattle, WA, USA) and SPSS ver-
sion 15.0 (SPSS, Chicago, IL, USA).
Results
Full data for 3,595 registrations in UMIN-CTR from 2 June
2005 to 1 June 2010
For research questions 1 and 2, three-step screening was
undertaken. First, 3,530 Japan domestic studies were
extracted. Subsequently, we excluded industry-funded
trials and obtained 3,267 studies. Finally, 488 observa-
tional studies were excluded and 2,779 clinical trials
were identified (Figure 1). For research question 3, all
3,595 registrations in the full dataset were included for
analyses. For research question 4, a total of 1,519 studies
conducted in Japan and registered in ClinicalTrials.gov
from 2 June 2005 to 1 June 2010 were identified. We ex-
cluded 110 observational studies and obtained 1,409
clinical trials.
Research question 1: Monthly registration numbers of
clinical trials
The monthly registration numbers in UMIN-CTR from
2 June 2005 to 1 June 2010 are shown in Figure 2. A
peak of registration was observed in September 2005
(n = 112). After the peak, the monthly registration re-
mained at <40 from October 2005 to May 2008. From
June 2008, this pattern began to change and the number
of registrations started to increase with fluctuations. From
April 2009, the registration entered a period of steady and
rapid growth. One year later, the monthly registration
reached 129, which was the highest record since the startof UMIN-CTR. The number of registrations in June 2010
was only 21 because we only included the trials registered
on the first day of that month.
Research question 2: Overall characteristics of registered
trials
The results of the analysis of items of primary concern
are summarized in Table 4. Trials focusing on malig-
nancy accounted for nearly half of all trials (47.8%). Only
8.3% of trials used genomic information while they were
being carried out. With regard to the trial characteris-
tics, the prevalence of confirmatory/exploratory trials
was 36.3% versus 27.4%, whereas that of explanatory/
pragmatic trials was 11.7% versus 38.9%. Since these two
items did not have to be registered, appreciable data
were missing.
Parallel comparisons (48.0%) and single arms (46.4%)
were the designs most often used in all trials. There were
more non-randomized trials (51.6%) than randomized tri-
als (48.4%). Most trials were open without any blinding
(78.5%) or only the assessors were blinded (10.7%). Only
6.5% of trials had a double-blind design. A total of 88.6%
(1,269/1,433) of non-randomized trials and 56.9% (1,242/
2,181) of unblinded trials were single-arm designs. Only
5.2% of trials were conducted with three arms.
‘Medicine’ was the most studied type of intervention
(74.6%) and ‘maneuver’ was also studied in many regis-
tered trials (16.0%). The target sample sizes of trials were
concentrated in the categories of 11 to 100 (64.1%) and
101 to 1,000 (26.1%). Trials with a sample size of >1,000
accounted for only 2.3% of all trials. Nearly 90% of all
trials were carried out for >12 months (13 to 36 months,
38.0%; 37 to 60 months, 22.0%; >60 months, 15.4%)
(Table 4).
The prevalence of publication and partial publication of
trial results in the registry were low (publication, 4.9%; par-
tial publication, 5.1%). Moreover, only 10.9% of all trials
disclosed the trial information before trial commencement.
The numbers of registered studies and active control stud-
ies classified by disease specialty are presented in Figure 3.
Hematology/oncology was the most studied field (n =
447). Many clinical trials (>300) were based on gastroenter-
ology, cardiology, and pneumology. Fewer than 10 trials
were identified in aesthetic surgery, laboratory medicine,
and blood transfusion. The prevalence of using an active
control in clinical trials exceeded 50% in 6 of 44 fields
(ranked from high to low: endocrinology/metabolism, in-
tensive care medicine, nephrology, cardiology, emergency
medicine, and infectious disease). These fields are high-
lighted in pink in Figure 3. A prevalence of <10% for using
an active control was observed in four fields (endocrine
surgery, blood transfusion, laboratory medicine, and aes-
thetic surgery). The overall prevalence for use of an active
control in clinical trials in UMIN-CTR was 34.5% (Table 4).
Figure 1 Screening for research questions 1 and 2.
Figure 2 Registration trend of clinical trials in UMIN-CTR. The total registration number from 2 June 2005 to 1 June 2010 is 2,779. Factor 1:
ICMJE announcement about clinical trial registration (September 2005) [9]. Factor 2: New 5-Year Clinical Trial Activation Plan (March 2007) [34].
Factor 3: Requirement for application for Health and Labour Sciences Research Grants (April 2007) [25]. Factor 4: Revised ICMJE announcement
about clinical trial registration (July 2008) [33]. Factor 5: Formation of JPRN as an ICTRP Primary Registry (October 2008) [17]. Factor 6: Ethical
Guidelines for Clinical Research (April 2009) [26]. ICMJE, International Committee of Medical Journal Editors; ICTRP, International Clinical Trials
Registry Platform; JPRN, Japan Primary Registries Network; UMIN-CTR, University Hospital Medical Information Network Clinical Trials Registry.
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Table 4 Items of primary concern
Category Number of
trials
%
1. Malignancy/others
Malignancy 1,327 47.8
Others 1,452 52.2
2. Genomic information
Used 230 8.3
Not used 2,549 91.7
3. Confirmatory/exploratory
Confirmatory 1,010 36.3
Exploratory 762 27.4
Missing data 1,007 36.2
4. Explanatory/pragmatic
Explanatory 326 11.7
Pragmatic 1,081 38.9
Missing data 1,372 49.4
5. Basic design
Parallel 1,334 48.0
Crossover 135 4.9
Factorial 17 0.6
Single-arm 1,289 46.4
Expanded access 4 0.1
6. Randomization
Randomized 1,346 48.4
Non-randomized 1,433 51.6
7. Blinding
Open 2,181 78.5
Assessor blinded 298 10.7
Single-blind (participants) 87 3.1
Single-blind (investigators and assessors) 33 1.2
Double-blind 180 6.5
8. Control
Placebo 187 6.7
No treatment 249 9.0
Active 959 34.5
Dose comparison 70 2.5
Historical 281 10.1
Uncontrolled 1,033 37.2
9. Number of arms
1 1,289 46.4
2 1,282 46.1
3 145 5.2
>4 63 2.3
10. Type of interventiona
Medicine 2,074 74.6
Table 4 Items of primary concern (Continued)
Vaccine 112 4.0
Genetic 16 0.6
Food 75 2.7
Device, equipment 273 9.8
Behavior, custom 133 4.8
Maneuver 445 16.0
Others 0 0.0
11. Target sample size
1 to 10 210 7.6
11 to 100 1,781 64.1
101 to 1,000 725 26.1
1001 to 1,0000 58 2.1
>10,000 5 0.2
12. Trial period (months)b
0 to 6 138 5.0
7 to 12 180 6.5
13 to 36 1,057 38.0
37 to 60 611 22.0
>60 428 15.4
Missing data 365 13.1
13. Report of resultsc
Unpublished 2,501 90.0
Published 136 4.9
Partially published 142 5.1
14. Disclosure of trial before/after trial
startd
Disclosure first 303 10.9
Trial start first 2,476 89.1
Total 2,779 100
aValues within this category are not mutually exclusive (total number: >2,779);
bperiod between trial start date and date of last patient’s final visit;
c‘published’: the final trial results were published regardless of the kind of
publication form (journals, academic conferences, webpages, and so on),
‘partially published’: only the results of interim analyses were published;
ddate of first enrollment was taken as the trial start date.
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account for a large proportion of all registered trials
(37.2%).
The results of the analysis of items of secondary concern
are shown in an additional file (see Additional file 1).
Research question 3: Accessibility of trials registered in
UMIN-CTR through ICTRP
The numbers of registrations classified according to
study ID type and study type are presented in Figure 4.
Among 3,595 registrations in UMIN-CTR from 2 June
2005 to 1 June 2010, 448 studies had a study ID begin-
ning with ‘C00000’, while the study IDs of the remaining
3,147 studies began with ‘UMIN’. Among the 448 studies
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were observational studies. With regard to the 3,147
studies beginning with ‘UMIN’, 2,641 were clinical trials
and 506 were observational studies. The total number of
clinical trials registered in UMIN-CTR during the 5-year
period was 3,064.
All 3,147 studies beginning with ‘UMIN’ were found in
the three-step search of ICTRP (step 1: 3,118; step 2: 11;
step 3: 18). Apart from study ‘C000000060’, all the other
447 studies beginning with ‘C00000’ were found in the
three-step search of ICTRP (step 1: 430; step 2: 8; step 3: 9).
Study ‘C000000060’ is a clinical trial, so all 3,064 clinical
trials except for one were accessible from ICTRP.
Research question 4: Accessibility of trials conducted in
Japan (with at least one listed site in Japan) but
registered abroad by Japanese people in the Japanese
language
Based on a search using downloaded data from
ClinicalTrials.gov, we identified 96 trials that were regis-
tered in Japanese registries and ClinicalTrials.gov
(UMIN-CTR, 50; Japic-CTI, 45; JMACCT, 0; UMIN-
CTR + Japic-CTI, 1). Based on a complementary search
of UMIN-CTR, Japic-CTI, and JMACCT, we identified a
further 27 trials that were also registered in Japanese
registries and ClinicalTrials.gov (UMIN-CTR, 23; Japic-
CTI, 4; JMACCT, 0). Therefore, 123 trials were found to
be registered in Japanese registries and ClinicalTrials.
gov. Such trials accounted for 8.7% (123/1,409) of all tri-
als conducted in Japan and registered in ClinicalTrials.
gov from 2 June 2005 to 1 June 2010 (Table 5).
According to the funder type, all 1,409 trials could
be classified as follows: industry-funded, 1,027; others-
funded, 352; industry + others-funded, 27; unknown
funder, 3. We compared the prevalence of registration in
Japanese registries in the three categories (industry-
funded; others-funded; industry + others-funded) by
Fisher’s exact test. We found a significant difference be-
tween these three categories (P <0.001). Industry-funded
trials had the lowest prevalence of registration in Japanese
registries (5.1%), while others-funded trials had the highest
prevalence (19.0%) (Table 5).
Among 1,286 trials that were only registered in
ClinicalTrials.gov, 975 (75.8%) trials were industry-
funded, 285 (22.2%) were others-funded, and 23 (1.8%)
were industry + others-funded.
Discussion
Research question 1: Monthly registration numbers of
clinical trials
The curve of the monthly registration numbers in
UMIN-CTR can be divided into four stages: 1) peak
(around September 2005); 2) stationary (October 2005 to
May 2008); 3) slow increase with fluctuations (June 2008to March 2009); and 4) rapid and steady increase
(April 2009 to April 2010).
To explain the observed peak around September 2005
in stage 1, the ICMJE announcement published in 2004 is
considered to be the most important factor. In this an-
nouncement, ICMJE member journals required the re-
gistration of a clinical trial in a public registry before
enrollment of patients as a condition of consideration for
publication [9]. This policy was applied from 1 July 2005.
For trials that began enrollment before this date, ICMJE
member journals required registration by 13 September
2005. Considering that publication is an important motiv-
ation for initiating clinical trials, conditions for publication
may have substantial effects on registration behaviors. A
similar peak around September 2005 was also observed in
the analysis of ClinicalTrials.gov conducted in 2005 by
Zarin et al. [28].
However, the monthly registrations obviously decreased
after this peak and remained at <40 for approximately 2.5
years (stage 2). The requirement for clinical trials to be
registered in Japanese registries as a pre-condition for ap-
plications for Health and Labour Sciences Research
Grants from April 2007 did not show any obvious effect
on the registration trend.
The situation changed from June 2008 when the
monthly registration curve entered a stage of slow increase
with fluctuations (stage 3). In 2007, the ICMJE revised
their announcement about clinical trial registration and
expanded the scope of registration to include all clinical
trials involving humans [33], whereas the announcement
in 2004 did not require the registration of trials studying
pharmacokinetics and major toxicity. The revised version
was applied from July 2008, and could have been one pos-
sible factor for the increase in monthly registrations. Other
factors that could have promoted the increase in registra-
tion were the New 5-Year Clinical Trial Activation Plan is-
sued by the Japanese government (MEXT/MHLW) in
March 2007 [34] and the formation of JPRN as an ICTRP
Primary Registry in October 2008.
From April 2009, it can be observed from Figure 2 that
the curve started to increase rapidly and steadily (stage 4).
The Ethical Guidelines for Clinical Research issued in
April 2009 may have exerted an important positive effect
on the registration of clinical trials in Japan.
Research question 2: Overall characteristics of registered
trials
We compared the results of analyses of UMIN-CTR
with reports from similar studies: 1) study on ICTRP by
Viergever and Ghersi in 2011 (including data registered
from 17 June 2008 to 17 June 2009 in nine registries
around the world) [35]; and 2) study on ClinicalTrials.
gov by Califf et al. in 2012 (including data in the fields
of oncology, cardiovascular, and mental health,
Figure 3 Disease-classified registration numbers by specialty and control type. The total number of registrations is 2,779. The registration
numbers in different subcategories are not mutually exclusive. Six subcategories with a prevalence of <50% for using an active control are
highlighted in pink. #All data labels: total number (number of active controls, percentage of active controls). *No active control: placebo, no
treatment, dose comparison, historical, uncontrolled.
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Such studies reflect the global situation to some extent.
Some obvious differences in the characteristics of reg-
istered clinical trials between UMIN-CTR, ICTRP, and
ClinicalTrials.gov were found. With regard to the basic
design, 46.4% of trials in UMIN-CTR adopted a single
arm without a control group. This prevalence was obvi-
ously higher than those reported for ICTRP (162/731,
22.2%) and ClinicalTrials.gov (12,144/40,970, 29.6%). Al-
though a single-arm design is frequently used in phase I
and phase II trials, and especially in oncology settings,
an appropriate control group is considered a key point
for obtaining rigorous and informative evidence from
clinical trials. Using a historical control from other stud-
ies for comparison may be feasible in single-arm trials,
but the validity of results from such comparisons cannot
be considered to be high, as different studies may varyquite a lot in their study design and other aspects. The
reasons for the comparatively high prevalence of single-
arm designs among the trials registered in UMIN-CTR
require further exploration.
Single-arm designs need neither randomization nor
blinding, and may be carried out with fewer participants.
Therefore, the high prevalence of single-arm designs also
influenced these characteristics of the registered trials. We
found that a large part of the non-randomized and un-
blinded trials followed a single-arm design. The prevalence
of randomized trials in UMIN-CTR was 48.4%, being
lower than those in ICTRP (518/731, 70.9%) and
ClinicalTrials.gov (27,027/40,970, 66.0%). The prevalence
of unblinded trials was higher in UMIN-CTR than in
ClinicalTrials.gov (78.5% versus 54.2%), while the preva-
lence of double-blind trials was lower in UMIN-CTR than
in ClinicalTrials.gov (6.5% versus 32.2%). Moreover, the
Figure 4 Numbers of registrations classified by study ID and study type.
Tang et al. Trials 2013, 14:333 Page 12 of 16
http://www.trialsjournal.com/content/14/1/333prevalence of using three arms in clinical trials, such as
intervention/active control/placebo, was very low (5.2%)
in UMIN-CTR. When analyzing the target sample
size, it was found that the trials in ClinicalTrials.gov
tended to enroll more participants (101 to 1,000:
33.8%; >1,000: 3.9%) than the trials in UMIN-CTR
(101 to 1,000: 26.1%; >1,000: 2.3%).
To explain the above differences in the trial characteris-
tics between UMIN-CTR and ICTRP/ClinicalTrials.gov, it
should be considered that all industry-funded trials were
excluded from our analysis of UMIN-CTR, but were in-
cluded with a prevalence of 44.0% in the analyses of bothTable 5 Clinical trials conducted in Japan and registered in C
Clinical trial Trials only
registered in
ClinicalTrials.
gov
Trials register
UMIN
Industry-funded 975 2
(94.9%) (0.2%)
Others-funded 285 67
(81.0%) (19.0%)
Industry + others funded 23 4
(85.2%) (14.8%)
Unknown funding sourcea 3 0
(100.0%) (0.0%)
Total 1,286 73
(91.3%) (5.2%)
Number (percentage calculated with numbers in the last column). aRecorded as ‘int
Pharmaceutical Information Center Clinical Trials Information; UMIN-CTR, UniversityICTRP and ClinicalTrials.gov. Moreover, the object and
period for the analysis of UMIN-CTR were not completely
identical with those for ICTRP and ClinicalTrials.gov.
However, the differences in the trial characteristics be-
tween UMIN-CTR and ICTRP/ClinicalTrials.gov may
imply the need for improvement in the design of clinical
trials in Japan.
In recent years, comparative effectiveness research
(CER) has been drawing increasing attention from pa-
tients, clinicians, policymakers, and healthcare payers for
its expected role in supporting evidence-based decision-
making in clinical practice and health policy [37,38].linicalTrials.gov (2 June 2005 to 1 June 2010)
ed in Japanese registries and ClinicalTrials.gov Total
Japic UMIN/Japicb Subtotal
49 1 52 1,027
(4.8%) (0.1%) (5.1%) (100.0%)
0 0 67 352
(0.0%) (0.0%) (19.0%) (100.0%)
0 0 4 27
(0.0%) (0.0%) (14.8%) (100.0%)
0 0 0 3
(0.0%) (0.0%) (0.0%) (100.0%)
49 1 123 1,409
(3.5%) (0.1%) (8.7%) (100.0%)
ervention’; bregistered in UMIN-CTR and Japic-CTI. Japic-CTI, Japan
Hospital Medical Information Network Clinical Trials Registry.
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comparing different interventions and strategies to pre-
vent, diagnose, treat, and monitor health conditions.
Considering that one of the key characteristics of CER is
the direct comparison of effective interventions [37] (ex-
cept for some diseases without effective intervention
in current practice), most CER originates from studies
using an active control. According to our analysis of
UMIN-CTR, 34.5% of trials adopted an active control.
This prevalence is higher than that reported by another
study analyzing trials conducted in the USA on 15 spe-
cific research areas and registered in ClinicalTrials.gov
from January 2007 to April 2010 (22.3%) [39].
With regard to this difference in the prevalence of active
control use between our analysis of UMIN-CTR and that
of ClincalTrials.gov, the different research design wherein
industry-funded trials were excluded from our analysis but
included in the analysis of ClinicalTrials.gov should be
considered. In addition, the analysis of ClinicalTrials.gov
examined trials conducted in only 15 specific research
areas whereas no such specification was made in our re-
search. Besides the differences in research design, two
other factors may lead to the comparatively high preva-
lence of active control use found in our analysis. The first
is the strong interest in CER by Japanese investigators of
academic clinical trials. The second is the different percep-
tion of active/placebo control and preferences between
Japanese and American investigators and patients. More
detailed studies concerning these two factors are expected
to promote the future development of CER.
Pragmatic trials are considered to be better aligned
with CER than explanatory trials because of their fea-
tures, such as using more active controls instead of pla-
cebo, including broader study populations, and assessing
more patient-centered outcomes [40]. Apart from 1,372
missing data, we discovered that 1,081/1,407 (76.8%) of
the trials registered in UMIN-CTR were labeled as ‘prag-
matic trials’. However, the overall prevalence of using an
active control was far lower (34.5%), even in addition to
trials with a ‘no treatment’ control (9.0%), which can
study conditions without an available active control. Ac-
tually, in UMIN-CTR, the registration of pragmatic/ex-
planatory trials is based on the registrant’s judgment and
we are not sure whether the statistics reflect the true
situation. There is no absolute boundary between prag-
matic trials and explanatory trials. Pragmatic features
and explanatory features may exist simultaneously in dif-
ferent dimensions of one trial [41]. Sometimes judging
whether a trial is pragmatic or explanatory is difficult.
Moreover, although many trials that adopted a single-
arm design may be labeled as ‘pragmatic’ because of
their pragmatic features in certain dimensions, such as
study population and outcomes, they cannot become
CER because they lack a control group.The studies in 2011 by Viergever and Ghersi [35] and
2012 by Califf et al. [36] also reported the situation of
retrospective registration. Retrospective registration (trial
registration after enrollment of the first patient) may
cause intended modification of the original protocols to
obtain positive results [35]. The ICMJE and WHO de-
clared that they require prospective registration of clin-
ical trials before enrollment of the first patient. However,
only 10.9% of the trials in our analysis of UMIN-CTR
were registered (disclosure of trial information) before
trial commencement (enrollment of first patient). This
value remained low compared with reports from studies
on ICTRP (26.0%) and ClinicalTrials.gov (48.0%).
With respect to publication of trial results, 90.0% of the
trials in our analysis were unpublished. This may imply
publication bias to some extent. However, almost all trials
were registered as ‘unpublished’ when they were first reg-
istered, and some registrants may forget to update re-
gistered trial information after they have published trial
information. Hence, such trials remain ‘unpublished’. In
addition, some trials that are ongoing or submitting their
results to medical journals were included in our analysis.
Hence, the accurate prevalence of publication of these tri-
als needs to be examined in more detail.
Research question 3: Accessibility of trials registered in
UMIN-CTR through ICTRP
The reason why study ‘C000000060’ was not found in
the search of ICTRP remains unclear. Our search strat-
egy for ICTRP may not be sufficient to find all the stud-
ies imported from UMIN-CTR. However, it can be seen
that, with the exception of this one trial, all 3,063 other
clinical trials registered in UMIN-CTR during the 5-year
period could be accessed by people around the world
through ICTRP in the English language. Individuals can
browse the 20-item dataset of these trials in ICTRP and
visit the webpage for each trial in UMIN-CTR through a
linked URL for more detailed information. UMIN-CTR
is considered to contribute positively to the improve-
ment of transparency and accessibility of clinical trials
around the world.
Research question 4: Accessibility of trials conducted in
Japan (with at least one listed site in Japan) but
registered abroad to Japanese people in the Japanese
language
Our analysis showed that among the clinical trials con-
ducted in Japan and registered in ClinicalTrials.gov from 2
June 2005 to 1 June 2010, only 8.7% were also registered
in Japanese registries to be accessible in the Japanese lan-
guage. A total of 1,286 clinical trials conducted in Japan
were only registered in ClinicalTrials.gov in the English
language. Considering the language difference, the accessi-
bility of the information for those trials to Japanese
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clinical trial is conducted in Japan and intended to be reg-
istered in UMIN-CTR, in accordance with the UMIN-
CTR principle introduced in the Methods section, it must
be registered not only in English but also in Japanese. The
language problem in clinical trial registration has been
discussed by other researchers [42]. We consider that pro-
viding information for clinical trials conducted in one
country not only in English, but also in the first language
of that country (if not English) has positive effects on ful-
filling the ethical obligations of clinical trials, facilitating
local people’s understanding of clinical trials, and promot-
ing the development of clinical trial enterprises across that
country.
When analyzing the type of funding source in the tri-
als identified in our analysis, industry-funded trials were
found to have a significantly lower prevalence (5.1%) of
registration in Japanese registries than others-funded tri-
als (19.0%) and industry + others-funded trials (14.8%)
(Table 5). Industry-funded trials also accounted for
75.8% of the trials that were conducted in Japan but not
registered in Japanese registries. Most industry-funded
trials conducted in Japan are trials for new drug applica-
tion and post-marketing clinical trials. At present, no
legal document or ethical guideline in Japan requires the
registration of such trials in Japanese registries. Even the
ICMJE announcement requires only trial registration in
any one of the registries acceptable to the ICMJE. Con-
sidering that it is not necessary to register a trial in more
than one registry, many registrants may choose to only
register trials in ClinicalTrials.gov because it is well-
known around the world. Moreover, for global trials
conducted simultaneously in Japan and the USA, regis-
tration in ClinicalTrials.gov is mandated by FDAAA 801
[30]. Hence, even if a trial also recruits patients from
Japan, the trial information is likely to be only registered
in ClinicalTrials.gov in the English language. However,
we feel that exploration of how to improve the accessi-
bility of such trials by Japanese people in the Japanese
language is justifiable for the positive effects of first lan-
guage registration as described above.
The prevalence of registration in Japanese registries
among others-funded and industry + others-funded tri-
als was not high. Most others-funded trials conducted
in Japan are not trials for new drug application or
post-marketing clinical trials. Although the Ethical
Guidelines for Clinical Research issued by the MHLW
have required the registration of such trials in Japanese
registries since April 2009, its influence may not be
well reflected in our analysis because we only included
trials registered before 1 June 2010. The effects of the
Ethical Guidelines for Clinical Research on Japanese
clinical trial registration need to be observed in future
studies.Limitations
Our research had some limitations. First, we did not in-
clude industry-funded trials or multinational trials not
only conducted in Japan in research questions 1 and 2.
Thus, our analyses do not reflect the characteristics of
such trials. To investigate such trials, other clinical trial
registries such as Japic-CTI (in which a large number of
industry-funded trials are registered) and foreign regis-
tries (such as ClinicalTrials.gov) should be used.
Second, although we focused our analysis on academic
clinical trials for research questions 1 and 2 by excluding
industry-funded trials, this screening is merely based on
the main funding source registered by the trial registrants.
However, many clinical trials (especially large-scale trials)
are funded by multiple sources and some clinical trials la-
beled as ‘self-funded’ or ‘foundation-funded’ may receive
funds from industry. Hence, some industry-funded trials
were inevitably included in our analyses for research ques-
tions 1 and 2. As Sawata and Tsutani [43] pointed out in
their research, the problem of an unclear funding source
is present in many Japanese clinical trials. Legislation or
guidelines for the disclosure of real funding sources in
clinical trials by the Japanese government and the corre-
sponding improvement of the current clinical trial regis-
tration system are considered to be the solutions to this
problem.
Third, we used ClinicalTrials.gov as a sample in the
analysis for research question 4 to reveal the problem of
accessibility of clinical trials conducted in Japan but reg-
istered abroad to Japanese people in the Japanese lan-
guage. However, clinical trials conducted in Japan and
registered in foreign registries other than ClinicalTrials.
gov were not included in our analysis. This is only pri-
mary research, and more detailed studies on this topic
are expected in the future.Conclusions
The present study is the first analysis of UMIN-CTR,
which is the largest clinical trial registry in Japan, utilizing
the information for registered clinical trials in the first 5
years since its establishment. We focused our research on
Japan domestic, academic clinical trials in UMIN-CTR,
and analyzed the registration trend and overall character-
istics of those trials. The ICMJE announcements about
clinical trial registration and the Ethical Guidelines for
Clinical Research issued by the Japanese government are
considered to have been positive factors in promoting
clinical trial registration in UMIN-CTR. In regard to trial
design, many trials adopted a single-arm design. Such tri-
als may limit the overall quality of clinical trials and the
development of CER in Japan. The reasons behind this
phenomenon need to be explored in the future. Moreover,
the problems of retrospective registration and possible low
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lenges for trial registration in UMIN-CTR.
We conducted a primary investigation on the accessibil-
ity of clinical trials registered in UMIN-CTR to people
around the world through ICTRP, as well as the accessibil-
ity of clinical trials conducted in Japan (with at least one
listed site in Japan) but registered abroad to Japanese
people in the Japanese language. Almost all clinical trials
registered in UMIN-CTR can be accessed by people
around the world through ICTRP. On the other hand,
many trials conducted in Japan but registered abroad can-
not be accessed by Japanese people in the Japanese lan-
guage. The aspect of how to improve the accessibility of
such trials in the Japanese language (especially industry-
funded trials) deserves further consideration.
Additional file
Additional file 1: Title of data: Items of secondary concern.
Description of data: Results of analysis on items of secondary concern.
Abbreviations
CER: comparative effectiveness research; CONSORT: Consolidated Standards
of Reporting Trials; EFPIA: European Federation of Pharmaceutical Industries
and Associations; FDA: Food and Drug Administration; FDAAA: Food and
Drug Administration Amendments Act; FDAMA: Food and Drug
Administration Modernization Act; GCP: Good Clinical Practice;
ICMJE: International Committee of Medical Journal Editors;
ICTRP: International Clinical Trials Registry Platform; IDE: investigational device
exemption; IFPMA: International Federation of Pharmaceutical Manufacturers
& Associations; IND: Investigational New Drug application; Japic-CTI: Japan
Pharmaceutical Information Center Clinical Trials Information; JMACCT: Japan
Medical Association Center for Clinical Trials; JPMA: Japanese Pharmaceutical
Manufacturers Association; JPRN: Japan Primary Registries Network;
MEXT: Ministry of Education, Culture, Sports, Science and Technology;
MHLW: Ministry of Health, Labour and Welfare; MHW: Ministry of Health and
Welfare; NIH: National Institutes of Health; NIPH: National Institute of Public
Health; PAL: Pharmaceutical Affairs Law; PhRMA: Pharmaceutical Research
and Manufacturers of America; PMDA: Pharmaceuticals and Medical Devices
Agency; RCT: randomized controlled trial; UMIN-CTR: University Hospital
Medical Information Network Clinical Trials Registry; WHO: World Health
Organization.
Competing interests
All the authors declare that they have no competing interests.
Authors’ contributions
HI, KT, and TK conceived and designed the study. MF and WT conducted the
statistical analyses for all research questions. HI and TK were responsible for
data acquisition. WT wrote the first draft of the manuscript. All authors read
and approved the final manuscript.
Acknowledgments
We thank Yamada Hiroyuki who is a technical expert at UMIN Center, The
University of Tokyo Hospital, Japan, for providing technical support with the
analyses for research questions 3 and 4.
Author details
1Department of Drug Policy and Management, Graduate School of
Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku,
Tokyo 113-0033, Japan. 2UMIN Center, The University of Tokyo Hospital,
Tokyo, Japan. 3Department of Health Communication, School of Public
Health, The University of Tokyo, Tokyo, Japan.Received: 2 May 2013 Accepted: 27 September 2013
Published: 14 October 2013
References
1. Dickersin K, Min YI: Publication bias: the problem that won’t go away.
Ann N Y Acad Sci 1993, 703:135–146.
2. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG: Empirical
evidence for selective reporting of outcomes in randomized trials:
comparison of protocols to published articles. JAMA 2004,
291(20):2457–2465.
3. Al-Marzouki S, Roberts I, Evans S, Marshall T: Selective reporting in clinical
trials: analysis of trial protocols accepted by The Lancet. Lancet 2008,
372(9634):201.
4. Dickersin K, Rennie D: Registering clinical trials. JAMA 2003, 290(4):516–523.
5. Levine J, Guy W, Cleary P: Therapeutic trials of psychopharmacologic
agents: 1968–1972. In Psychopharmacological Agent. Edited by McMahon
GA. Armonk, NY: Futura Publishing Co; 1974.
6. Simes RJ: Publication bias: the case for an international registry of clinical
trials. J Clin Oncol 1986, 4(10):1529–1541.
7. Missing drug data. Washington Post 30 June 2004:A20.
8. When drug companies hide data. New York Times 6 June 2004(Sect 4):12.
9. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S,
Laine C, Marusić A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden
MB: Clinical trial registration: a statement from the International
Committee of Medical Journal Editors. Lancet 2004, 364(9438):911–912.
10. Krleza-Jerić K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C: Principles
for international registration of protocol information and results from
human trials of health related interventions: Ottawa statement (part 1).
BMJ 2005, 330(7497):956–958.
11. World Health Organization (WHO): WHA58.34 Ministerial Summit on Health
Research. Geneva: WHO; 2005 [http://apps.who.int/iris/bitstream/10665/
20384/1/WHA58_34-en.pdf]
12. International Clinical Trials Registry Platform (ICTRP) Search Portal. [http://apps.
who.int/trialsearch/]
13. International Clinical Trials Registry Platform (ICTRP): WHO Trial Registration Data
Set (Version 1.2.1). [http://www.who.int/ictrp/network/trds/en/index.html].
14. World Medical Association (WMA): WMA Declaration of Helsinki - Ethical
Principles for Medical Research Involving Human Subjects. Ferney-Voltaire:
WHO; 2008 [http://www.wma.net/en/30publications/10policies/b3/].
15. CONSORT Statement: Item 23 - Registration number and name of trial registry.
[http://www.consort-statement.org/consort-statement/23-25—other-
information0/]
16. UMIN Clinical Trials Registry (UMIN-CTR). [http://www.umin.ac.jp/ctr/index-j.htm].
17. Shiokawa T: Background, introduction and activity of the Japan Primary
Registries Network. J Evid Based Med 2009, 2(1):41–43.
18. Japic-CTI: [http://www.clinicaltrials.jp]
19. JMACCT: [https://dbcentre3.jmacct.med.or.jp/jmactr/]
20. Yakuji Hoki Kenkyukai (The Society of Pharmaceutical Laws and Regulations):
Roppozensyo (Compendium of the six codes). Tokyo: Gyosei Press; 2013.
21. Shin Iyakuhin Nado no Shiyo no Seiseki Nado ni Kansuru Cyosa Jisshi
Keikakusyo ni tsu i te (the notification of protocol of use results surveys on new
drugs). [http://www.japal.org/contents/19931228_113.pdf]
22. Yakubutsu no Chiken Keikaku Todokede Seido (the system of notification of
Chiken protocol). [http://www.pmda.go.jp/operations/shonin/info/
chikenkanren/chikentodoke.html]
23. International Federation of Pharmaceutical Manufacturers & Associations
(IFPMA): Global Industry Position On Disclosure of Information About Clinical
Trials. Geneva: IFPMA; 2005 [http://clinicaltrials.ifpma.org/clinicaltrials/
fileadmin/files/pdfs/EN/CTP_Release_Joint_Position_EN.pdf]
24. International Federation of Pharmaceutical Manufacturers & Associations
(IFPMA): New Joint Industry Clinical Trials Transparency Position Requires
Companies to Disclose All Clinical Trials in Patients. Geneva: IFPMA; 2009 [http://
www.jpma.or.jp/about/basis/rinsyo/pdf/091110_shishin_release_e.pdf]
25. Heisei 19 Nendo Koseirodo Kagaku Kenkyuhi Hojyokin Kobo Yoko (requirement
for the application of Health and Labour Sciences Research Grants). [http://
www.mhlw.go.jp/bunya/kenkyuujigyou/hojokin-koubo07b/index.html]
26. Rinsyo Kenkyuni Kansuru Rinri Shishin (ethical guidelines for clinical research).
[http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/rinsyo/dl/shishin.pdf]
27. Tashiro S: Unintended consequences of “soft” regulations: the social
control of human biomedical research in Japan. Int J Jpn Sociology 2010,
19(1):4–17.
Tang et al. Trials 2013, 14:333 Page 16 of 16
http://www.trialsjournal.com/content/14/1/33328. Zarin DA, Tse T, Ide NC: Trial Registration at ClinicalTrials.gov between
May and October 2005. N Engl J Med 2005, 353(26):2779–2787.
29. ClinicalTrials.gov. [http://www.clinicaltrials.gov]
30. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC: The ClinicalTrials.gov results
database–update and key issues. N Engl J Med 2011, 364(9):852–860.
31. UMIN-CTR no Unei Hoshin (operation policy of UMIN-CTR). [http://www.umin.
ac.jp/ctr/UMIN-CTR_Policy.htm]
32. UMIN-CTR Yogo no Setsumei (simple glossary of UMIN-CTR). [http://www.
umin.ac.jp/ctr/UMIN-CTR_Yougo.htm]
33. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, Haug C,
Hébert PC, Kotzin S, Marusic A, Sahni P, Schroeder TV, Sox HC, Van der
Weyden MB, Verheugt FW: Clinical trial registration: looking back and
moving ahead. Lancet 2007, 369(9577):1909–1911.
34. Aratana Chiken Kaseika 5 ka Nen Keikaku (New 5-Years Clinical Trial Activation
Plan). [http://www.mhlw.go.jp/shingi/2007/03/s0330-5.html]
35. Viergever RF, Ghersi D: The quality of registration of clinical trials.
PLoS One 2011, 6(2):e14701.
36. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A:
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010.
JAMA 2012, 307(17):1838–1847.
37. Sox HC, Greenfield S: Comparative effectiveness research: a report from
the Institute of Medicine. Ann Intern Med 2009, 151(3):203–205.
38. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz
JS: Rethinking randomized clinical trials for comparative effectiveness
research: the need for transformational change. Ann Intern Med 2009,
151(3):206–209.
39. Bourgeois FT, Murthy S, Mandl KD: Comparative effectiveness research: an
empirical study of trials registered in ClinicalTrials.gov. PLoS One 2012,
7(1):e28820.
40. Mullins CD, Whicher D, Reese ES, Tunis S: Generating evidence for
comparative effectiveness research using more pragmatic randomized
controlled trials. Pharmacoeconomics 2010, 28(10):969–976.
41. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG,
Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K: A pragmatic-explanatory
continuum indicator summary (PRECIS): a tool to help trial designers.
J Clin Epidemiol 2009, 62(5):464–475.
42. Hasselblatt H, Dreier G, Antes G, Schumacher M: The German Clinical Trials
Register: challenges and chances of implementing a bilingual registry.
J Evid Based Med 2009, 2(1):36–40.
43. Sawata H, Tsutani K: Funding and infrastructure among large-scale clinical
trials examining cardiovascular diseases in Japan: evidence from a
questionnaire survey. BMC Med Res Methodol 2011, 11:148.
doi:10.1186/1745-6215-14-333
Cite this article as: Tang et al.: Review of the registration of clinical trials
in UMIN-CTR from 2 June 2005 to 1 June 2010 - focus on Japan
domestic, academic clinical trials. Trials 2013 14:333.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
